PROK_OUT_1 [2025-04-16 10:48:28 -0400] 3714 Bytes | 968 tokens | Cum: 968 tkns (12.10% of 8k)
==========================================================================

Alright, let’s light it up, because it's 10:48:28 AM on Wed Apr 16, 2025 -0400, and I'm charging into ProKidney (PROK), popping from 0.7101 to 0.8485. Is this our star stock of the day, or just a quick blip on the radar? I've got the scoop—time to analyze!

--- COMPANY PROFILE ---
Company: ProKidney (PROK)
IPO: IPO date unknown
Shares Outstanding: 129,539,999
Industry: BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES)
Exchange: XNAS

Here’s a list of headlines for ProKidney:

Mar-21-25 09:55AM - Down -38% in 4 Weeks, Here's Why You Should You Buy the Dip in PROKIDNEY CP (PROK)
Mar-17-25 07:30AM - ProKidney Reports Full Year 2024 Financial Results and Business Highlights
Jan-07-25 07:30AM - ProKidney to Present at the 43rd Annual J.P. Morgan Healthcare Conference
Nov-26-24 07:30AM - ProKidney to Participate in Two Upcoming Conferences: Evercore HealthCONx Conference and the Citi Global Healthcare Conference
Nov-12-24 07:30AM - ProKidney Reports Third Quarter 2024 Financial Results along with Regulatory and Clinical Development Updates Following Successful FDA Type B Meeting
Nov-05-24 07:30AM - ProKidney to Participate in the Guggenheim Inaugural Healthcare Innovation Conference and the Jefferies London Healthcare Conference
Oct-22-24 07:02PM - Suvretta Capital Management's Strategic Acquisition in ProKidney Corp
Oct-14-24 07:30AM - ProKidney Announces Five Abstracts Selected for Presentation at the American Society of Nephrology's Kidney Week 2024

Here's another list of headlines with menu handles.
I will deliver the full text of the following stories when you say their handle.
Just say, for example, B1, B2, etc.

B1 - 2024-06-21T10:55:00Z - Play Likely Earnings Beat With 3 Top-Ranked Stocks
B2 - 2024-06-12T01:35:00Z - ProKidney Announces Pricing of its Upsized $130 Million Public Offering of Class A Ordinary Shares and Concurrent Registered Direct Offering
B3 - 2024-06-10T20:15:00Z - ProKidney Announces Proposed $125 Million Public Offering of Class A Ordinary Shares and Concurrent Registered Direct Offering
B4 - 2024-06-10T10:30:00Z - ProKidney Announces Positive Interim REGEN-007 Phase 2 Trial Data and Provides Clinical and Operational Updates
B5 - 2024-05-10T11:00:00Z - ProKidney Reports Business Updates and First Quarter 2024 Financial Results
B6 - 2024-04-15T18:11:35Z - Why Ultragenyx Pharmaceutical Shares Are Trading Lower By Around 9%? Here Are Other Stocks Moving In Monday's Mid-Day Session

==============
-> THE ROLE FOR AI:
==============

1) You are the **AI analyst-investigator**, and this interaction represents a full **due diligence session** for ProKidney (PROK).
Due diligence includes financial data, insider trading, relevant news, and any SEC filings — and may extend beyond classic fundamentals.
Your task is to identify whether this stock has momentum and potential.

2) I am **ScanScor**, a unified report generator that archives this session as part of our real-time diligence record.

3) You will request information by referencing documents by their code.

4) As the analysis proceeds, your are encouraged to review documents until you feel confident in your judgment.
After seeing 3 sets of news articles, SEC docs, and financials, you'll be prompted to return some data pairs.

5) News articles, SEC filings, and key metrics will be revealed in subsequent prompts.

Stay focused. Gather evidence. Continue until your conclusions are clear.
Restrict all your responses to just 3 tokens until the summary and data pairs at the end.

NEXT: Request a document with its reference code(s), such as:
- `B1`, `B2`, `B3`, etc.
- To load a new set of information and menu options, reply with: `NEX`

PROK_OUT_3 [2025-04-16 10:48:29 -0400] 1189 Bytes | 313 tokens | Cum: 1283 tkns (16.04% of 8k)
==========================================================================

Showing B2 (chunk 1 of 2): B2:
**ProKidney Announces Pricing of its Upsized $130 Million Public Offering of Class A Ordinary Shares and Concurrent Registered Direct Offering**Date: Unknown DateSource: Unknown SourceURL: https://www.globenewswire.com/news-release/2024/06/12/2897248/0/en/ProKidney-Announces-Pricing-of-its-Upsized-130-Million-Public-Offering-of-Class-A-Ordinary-Shares-and-Concurrent-Registered-Direct-Offering.htmlWINSTON-SALEM, N.C., June 11, 2024 (GLOBE NEWSWIRE) -- ProKidney Corp. (Nasdaq: PROK) (“ProKidney” or the “Company”), a leading late clinical-stage cellular therapeutics company focused on chronic kidney disease, today announced the pricing of an underwritten public offering and a concurrent registered direct offering of 53,719,009 shares of its Class A ordinary shares at a price of $2.42 per share, before applicable underwriting discounts and commissions. In addition, the underwriters wil

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

PROK_OUT_5 [2025-04-16 10:48:31 -0400] 925 Bytes | 204 tokens | Cum: 1489 tkns (18.61% of 8k)
==========================================================================

Showing B2 (chunk 2 of 2): l have a 30-day option to purchase up to an additional 15% of the Class A ordinary shares sold in the underwritten public offering. All of the Class A ordinary shares in the underwritten public offering and concurrent registered direct offering are being sold by the Company. The public offering and the concurrent registered direct offering are each expected to close on or about June 13, 2024, subject to customary closing conditions. The underwritten public offering is not contingent on the closing of the concurrent direct offering, and the concurrent direct offering is not contingent on the closing of the underwritten public offering.

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

PROK_OUT_7 [2025-04-16 10:48:32 -0400] 926 Bytes | 276 tokens | Cum: 1767 tkns (22.09% of 8k)
==========================================================================

We present this news so you can catch the big movers from recently breaking news.
Here's a list of news articles you can literally read just by asking.
Usually the first item is the most important.

A1 - 2025-04-08T17:28:06Z - PROK stock touches 52-week low at $0.49 amid market challenges By Investing.com...
A2 - 2025-04-08T17:26:44Z - PROK stock touches 52-week low at $0.49 amid market challenges By Investing.com...
A3 - 2025-03-31T15:20:05Z - PROK stock touches 52-week low at $0.86 amid market challenges By Investing.com...
A4 - 2025-03-31T15:20:05Z - PROK stock touches 52-week low at $0.86 amid market challenges By Investing.com...
A5 - 2025-03-27T16:01:48Z - Here's Why We're Watching ProKidney's (NASDAQ:PROK) Cash Burn Situation...

Request an article by its reference number. (Ex., "A1" gets the first item)
You may also say NEX to go to the next listing.
Response to this prompt limited to 3 chars.

PROK_OUT_9 [2025-04-16 10:48:36 -0400] 1181 Bytes | 313 tokens | Cum: 2082 tkns (26.02% of 8k)
==========================================================================

Showing A1 (chunk 1 of 2): A1:
**PROK stock touches 52-week low at $0.49 amid market challenges By Investing.com**Date: 2025-04-08Source: {'uri': 'in.investing.com', 'dataType': 'news', 'title': 'Investing.com India'}URL: https://in.investing.com/news/company-news/prok-stock-touches-52week-low-at-049-amid-market-challenges-93CH-4765149ProKidney Corp (PROK) stock has hit a 52-week low, dropping to $0.49, as the company faces a challenging market environment. According to InvestingPro data, the company's financial health score is rated as WEAK, with the stock down nearly 29% in just the past week. This new low reflects a significant downturn from previous periods, with the stock experiencing a 1-year change of -65.17%. While the RSI indicates oversold conditions, the company's rapid cash burn rate and negative EBITDA of -$173M raise concerns. Investors are closely monitoring ProKidney's performance, as the company n

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

PROK_OUT_11 [2025-04-16 10:48:37 -0400] 726 Bytes | 167 tokens | Cum: 2251 tkns (28.14% of 8k)
==========================================================================

Showing A1 (chunk 2 of 2): avigates through the headwinds that have led to this decline. The 52-week low serves as a critical indicator for the company's valuation and is a key point of focus for stakeholders assessing the health and future prospects of ProKidney in the competitive biotechnology sector. With 15 additional key insights available on InvestingPro, investors can access comprehensive analysis to make more informed decisions about PROK's future potential.

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

PROK_OUT_13 [2025-04-16 10:48:38 -0400] 1102 Bytes | 301 tokens | Cum: 2554 tkns (31.92% of 8k)
==========================================================================

This is our list of SEC filings.
If empty, the search returned no recent filings.

S2 - 2025-03-17 10-K Item 7 . Mgts Discussion and Analysis of Fin Cond and Results of Oper.

As used in this Annual Report on Form 10-K, the Company, the Registrant, we or us refer to ProKidney Corp. and its subsidiaries. The following discussion and analysis of our financia...

S3 - 2025-03-17 8-K Item 2.02 Results of Oper and Fin Cond.

On March 17, 2025, ProKidney Corp. (the "Company") issued a press release to announce its financial results for the year ended December 31, 2024. A copy of the press release is furnished as Exhibit 99.1.

The information...

S10 - 2025-01-21 8-K Item 1.01 Entry into a Material Definitive Agrmt.

On January 17, 2025, ProKidney Corp. (the Company), through its wholly owned subsidiary, ProKidney Acquisition Company, LLC, entered into a purchase and sales agreement with Stream Realty Acquisition, L.L.C. (the Agrmt)...

Request filing by its reference number. (Ex., "S1" gets the first item)
You can say NEX to go to the next listing.
Response limited to 3 chars.

PROK_OUT_15 [2025-04-16 10:48:40 -0400] 1181 Bytes | 243 tokens | Cum: 2799 tkns (34.99% of 8k)
==========================================================================

Showing S2 (chunk 1 of 6): S2:
Item 7 . Managements Discussion and Analysis of Financial Condition and Results of Operations.

As used in this Annual Report on Form 10-K, the Company, the Registrant, we or us refer to ProKidney Corp. and its subsidiaries. The following discussion and analysis of our financial condition and results of operations should be read in conjunction with our financial statements and related notes that appear elsewhere in this report. In addition to historical financial information, the following discussion contains forward-looking statements that reflect our plans, estimates, assumptions and beliefs. Our actual results could differ materially from those discussed in the forward-looking statements. Factors that could cause or contribute to these differences include those discussed elsewhere in this report under Part IItem 1A, Risk Factors. Forward-looking statements include information con

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

PROK_OUT_17 [2025-04-16 10:48:41 -0400] 1181 Bytes | 244 tokens | Cum: 3045 tkns (38.06% of 8k)
==========================================================================

Showing S2 (chunk 2 of 6): cerning our possible or assumed future results of operations, business strategies and operations, financing plans, potential growth opportunities, potential market opportunities, potential results of our drug development efforts or trials, and the effects of competition. Forward-looking statements include all statements that are not historical facts and can be identified by terms such as anticipates, believes, could, seeks, estimates, expects, intends, may, plans, potential, predicts, projects, should, will, would or similar expressions and the negatives of those terms. Given these uncertainties, you should not place undue reliance on these forward-looking statements. Also, forward-looking statements represent our managements plans, estimates, assumptions and beliefs only as of the date of this report. Except as required by law, we assume no obligation to update these forward-looking sta

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

PROK_OUT_19 [2025-04-16 10:48:45 -0400] 1181 Bytes | 246 tokens | Cum: 3293 tkns (41.16% of 8k)
==========================================================================

Showing S2 (chunk 3 of 6): tements publicly or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future.

Overview

We are a clinical-stage biotechnology company with a transformative proprietary cell therapy platform that has the potential to treat multiple chronic kidney diseases using a patients own cells isolated from the patient intended for treatment. Our approach seeks to redefine the treatment of CKD, shifting the emphasis away from management of kidney failure to the preservation of kidney function. Our lead product candidate, rilparencel, is designed to preserve kidney function in a CKD patients diseased kidneys. Rilparencel is a product that includes autologous SRC prepared from a patients own kidney cells. SRC are formulated into a product for reinjection into the patients kidneys u

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

PROK_OUT_21 [2025-04-16 10:48:45 -0400] 1181 Bytes | 279 tokens | Cum: 3574 tkns (44.67% of 8k)
==========================================================================

Showing S2 (chunk 4 of 6): sing a minimally invasive outpatient procedure that is repeatable, if necessary. Because rilparencel is a personalized treatment composed of cells prepared from a patients own kidney, there is no need for treatment with immunosuppressive therapies that are required during a patients lifetime when a patient receives a kidney transplant from another, allogeneic donor.

We are currently conducting a Phase 3 development program and an ongoing Phase 2 clinical trial for rilparencel in subjects with moderate to severe CKD and diabetes. Rilparencel has received RMAT designation from the FDA. We also completed a Phase 1 clinical trial for rilparencel in subjects with CKD due to congenital anomalies of the kidney and urinary tract (CAKUT) for which

the last subject visit occurred in January 2023 and the clinical study report was submitted to the FDA in December 2023. Rilparencel has, to date,

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

PROK_OUT_23 [2025-04-16 10:48:46 -0400] 1181 Bytes | 232 tokens | Cum: 3808 tkns (47.60% of 8k)
==========================================================================

Showing S2 (chunk 5 of 6): been generally well tolerated by subjects with moderate to severe CKD in Phase 1 and 2 clinical testing.

Since our inception, we have devoted substantially all of our resources to organizing and staffing our Company, business and scientific planning, conducting discovery and research activities, acquiring or discovering product candidates, establishing and protecting our intellectual property portfolio, developing and progressing rilparencel, raising capital and preparing for clinical trials, establishing arrangements with third parties for the manufacture of component materials, and providing general and administrative support for these operations. We do not have any product candidates approved for sale and have not generated any revenue from product sales.

Other Trends and Uncertainties

We continue to monitor the impacts of ongoing macroeconomic conditions and geopolitical events

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

PROK_OUT_25 [2025-04-16 10:48:47 -0400] 790 Bytes | 161 tokens | Cum: 3971 tkns (49.64% of 8k)
==========================================================================

Showing S2 (chunk 6 of 6): . An escalation of geopolitical tensions or the implementation of global trade restrictions could adversely impact our business, financial condition or results of operations. Global conflicts, tariffs, labor disruptions, and regulations continue to create volatility in global markets and contribute to supply chain shortages and pricing volatility. We continue to actively collaborate with our suppliers to minimize shortages and reduce supply and price volatility.

Financial Operations Overview

Rev...

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

PROK_OUT_27 [2025-04-16 10:48:56 -0400] 8234 Bytes | 2268 tokens | Cum: 6241 tkns (78.01% of 8k)
==========================================================================

This is our set of metrics for ProKidney.
Please analyze the numbers.

+---------------------+-----------------------+-------------------------+----------------------+
| Volume: 284,261 | Perf Month: -15.25% | Option/Short: Yes / Yes | Sales Y/Y TTM: - |
+---------------------+-----------------------+-------------------------+----------------------+
| Avg Volume: 639.88K | Perf Quarter: -47.99% | Short Float: 12.76% | ROE: - |
+---------------------+-----------------------+-------------------------+----------------------+
| Rel Volume: 2.18 | Index: RUT | Short Ratio: 18.64 | ROI: - |
+---------------------+-----------------------+-------------------------+----------------------+
| RSI (14): 47.62 | Market Cap: 240.50M | Short Interest: 11.93M | Sales Surprise: - |
+---------------------+-----------------------+-------------------------+----------------------+
| ATR (14): 0.15 | Shs Outstand: 128.05M | Beta: 1.63 | EPS Surprise: -7.96% |
+---------------------+-----------------------+-------------------------+----------------------+
| SMA20: 3.46% | Shs Float: 93.47M | Sales Q/Q: - | P/E: - |
+---------------------+-----------------------+-------------------------+----------------------+
| SMA50: -24.93% | Inst Own: 44.18% | Sales past 5Y: 0.00% | Earnings: Mar 17 BMO |
+---------------------+-----------------------+-------------------------+----------------------+
| SMA200: -53.33% | Insider Own: 27.84% | Employees: 204 | |
+---------------------+-----------------------+-------------------------+----------------------+
| Perf Week: 41.06% | Insider Trans: 1.29% | Debt/Eq: - | |
+---------------------+-----------------------+-------------------------+----------------------+

The next section covers any insider trading by ProKidney officers or majority shareholders (if available).

Inside Trans: PROKIDNEY CORP. (PROK) by Control Empresarial de Capitales S.A. de C.V. (Unknown Title) on 2025-04-10
- Class A Ordinary Shares (as defined in Exhibit 99.1 hereto): 1032218 shares at $0.6081 (D)
- Class A Ordinary Shares (as defined in Exhibit 99.1 hereto): 1900 shares at $0.6081 (D)

Inside Trans: PROKIDNEY CORP. (PROK) by Coulston James (Chief Financial Officer) on 2025-03-01
- Employee stock option (right to buy): 650000 shares at $0 (D)

Inside Trans: PROKIDNEY CORP. (PROK) by Girolamo Todd C (Chief Legal Officer) on 2025-03-01
- Employee stock option (right to buy): 650000 shares at $0 (D)

Inside Trans: PROKIDNEY CORP. (PROK) by Weber Darin J. (Chief Regulatory Officer) on 2025-03-01
- Employee stock option (right to buy): 450000 shares at $0 (D)

Inside Trans: PROKIDNEY CORP. (PROK) by Culleton Bruce (Chief Executive Officer) on 2025-03-01
- Employee stock option (right to buy): 1796000 shares at $0 (D)

Inside Trans: PROKIDNEY CORP. (PROK) by Pereira Brian JG (Unknown Title) on 2025-02-04
- Class A Ordinary Shares: 81928 shares at $0 (D)
- Class A Ordinary Shares: 675234 shares at $0 (I)
- Class B Ordinary Shares: 81928 shares at $0 (D)
- Common Units in ProKidney LP: 81928 shares at $0 (D)
- Class B Ordinary Shares: 675234 shares at $0 (I)
- Common Units in ProKidney LP: 675234 shares at $0 (I)

Inside Trans: PROKIDNEY CORP. (PROK) by Legorreta Pablo G. (Unknown Title) on 2025-02-04
- Class A Ordinary Shares: 532535 shares at $0 (I)
- Class A Ordinary Shares: 532535 shares at $0 (I) Footnote: Prior to February 4, 2025 (the "Transaction Date"), Tolerantia held 88,639,961 Common Units in ProKidney and an equal number of Class B Ordinary Shares (the "Paired Interests"), 84,160,537 of which were held by Nefro Health, an Irish partnership that is an affiliate controlled and majority-owned by Mr. Pablo Legorreta, and 4,479,424 of which were held by other investors which are unaffiliated with Mr. Legorreta (the "Unaffiliated Investors"). On the Transaction Date, Tolerantia exchanged 532,535 of the 4,479,424 Paired Interests attributable to the interests of the Unaffiliated Investors in Tolerantia for 532,535 Class A Ordinary Shares, which it subsequently distributed in-kind pro rata for no consideration to the Unaffiliated Investors.
- Class B Ordinary Shares: 532535 shares at $0 (I)
- Common Units in ProKidney LP: 532535 shares at $0 (I)

[Company Financial Summary]
[Company Details]
Name: N/A
Market Cap: N/A
Shares Outstanding: N/A
Sector: N/A

[Financial Statements - Latest Quarter]
Total Assets: N/A
Total Liabilities: N/A
Total Equity: N/A
Revenue (Quarter): {'value': 76000, 'unit': 'USD', 'label': 'Revenues', 'order': 100}
Net Income: {'value': -163335000.0, 'unit': 'USD', 'label': 'Net Income/Loss', 'order': 3200}
Earnings Per Share (EPS): N/A

[Price Metrics - Last 30 Days]
Latest Close: 0.8433
Average Volume: 919508.43
30-Day High: 1.04
30-Day Low: 0.5109

[Detailed Financials: TTM 2024]
- Total Assets: $441,073,000.0
- Total Liabilities: $39,436,000.0
- Total Equity: $-994,954,000.0
- Current Assets: $395,884,000.0
- Current Liabilities: $36,217,000.0

[Income Statement: TTM 2024]
- Revenue: $76,000.00
- Net Income: N/A
- Gross Profit: N/A
- Operating Income: N/A
- Earnings Per Share (EPS): N/A

[Cash Flow Statement: TTM 2024]
- Net Cash Flow: $38,471,000.0

[Detailed Financials: FY 2024]
- Total Assets: $441,073,000.0
- Total Liabilities: $39,436,000.0
- Total Equity: $-994,954,000.0
- Current Assets: $395,884,000.0
- Current Liabilities: $36,217,000.0

[Income Statement: FY 2024]
- Revenue: $76,000.00
- Net Income: N/A
- Gross Profit: N/A
- Operating Income: N/A
- Earnings Per Share (EPS): N/A

[Cash Flow Statement: FY 2024]
- Net Cash Flow: $38,471,000.0
==== END OF FINANCIAL REPORT ====

You are now requested to write a summary analysis of ProKidney (PROK).

Please complete the report using the exact format:
FIELD[value]

1) BRIEF_SUMMARY[]
One well-worded paragraph summarizing your findings about ProKidney.

2) MARKET_SCORE[]
This conversation was initiated because PROK is currently experiencing upward price and volume movement.
Estimate a number between 1–100 based on the likelihood of a continued upward price move for PROK.
Weigh relevant data — news, filings, fundamentals, and metrics — and assign appropriate weight.

3) PRICE_TARGET[]
Suggest a price, based on all prior evidence and past price behavior, PROK could reach in the current or upcoming trading sessions (1–5 days).
For example, if you expect PROK to increase 50% from its current price of $0.00, say: PRICE_TARGET[0.0]

4) AI_RPT_HEADLINE[]
Write a thought-provoking 8–12 word headline summarizing this report.

5) SQUEEZE_POTENTIAL[]
Give a score from 1 to 100 representing the potential for this stock to become an active short squeeze play.
Be honest and unbiased. Consider short interest/float, price movement, volume, news strength, and volatility potential.

6) TAGS[]
List 3–6 comma-separated tags (e.g., biotech, earnings beat, squeeze setup)

7) STOCK_TYPE[]
Choose the most accurate classification: growth, value, turnaround, hype, squeeze, dividend, speculative, or other.

8) PRIMARY_CATALYST[]
e.g., earnings report, FDA approval, partnership, etc.

9) SENTIMENT[]
bullish, bearish, neutral, or mixed

10) IMPROVEMENT_SUGGESTION[]
If you believe some key info was missing, state what would have significantly improved your analysis of ProKidney.

11) ETHICAL_RATING[]
Rate ProKidney’s alignment with long-term shareholder interests, using a letter grade from A (high alignment) to F (low alignment).
Base this on actions such as insider buying/selling, share dilution, follow-through on public statements, and compensation practices.

12) UPCOMING_CATALYST[]
Specify any upcoming events you expect would be a catalyst affecting the share-price of ProKidney.
Provide any reasons you can use to support it.

Return only: FIELD[value] for each of the above 12 questions.
Respond with all data pairs. Take your best guess if you have to, but don't leave blank items.
Do not explain your answers. Return only the required fields in the exact format shown.

Finally, thank you for participating!

PROK_IN_29 [2025-04-16 10:48:56 -0400] 126 Bytes | 29 tokens | Cum: 6493 tkns (81.16% of 8k)
==========================================================================

====================================
[2025-04-16 10:48:56] # Analysis Completed
Elapsed Time: 28.67 seconds